Study to Investigate Safety and Response to 1 or 2 g Rectal Suppositories Containing 5 or 10 mg NRL001.
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a healthy volunteer three-way crossover study. A total of 12 subjects will receive
three single administrations of 1 g rectal suppositories (containing either 5 mg NRL001, 10
mg NRL001 or matching placebo), with a washout period of at least 7 days between dosings. A
further 12 subjects will receive three single administrations of 2 g rectal suppositories
(containing either 5 mg NRL001, 10 mg NRL001 or matching placebo), again with a 7 day washout
period between dosings. The pharmacodynamic response, pharmacokinetics and safety profile
will be determined.